Epigenetic Epitype Classification for AML Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for classifying and treating acute myeloid leukemia (AML) and other cancers fail to account for epigenetic modifications, which are crucial for understanding disease heterogeneity and clinical outcomes.
Innovation Solution
The use of DNA methylation patterns to identify specific epigenetic signatures, categorize patients into epitypes, and administer targeted treatments based on these signatures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If DNA methylation analysis is integrated into AML classification, then disease classification accuracy and treatment effectiveness improve, but diagnostic complexity and testing requirements increase
Solution Approach 1:
The patent segments the complex epigenetic landscape into discrete, actionable categories by defining 13 distinct epitypes based on DNA methylation patterns. Each epitype represents a simplified classification unit that captures specific disease states, making the complex information manageable and clinically actionable without requiring analysis of the entire epigenome.
Solution Approach 2:
The patent transforms the continuous spectrum of DNA methylation data into discrete categorical parameters (epitypes 1-13). This parameter transformation converts complex quantitative epigenetic measurements into simplified qualitative classifications that can be directly mapped to treatment protocols, reducing diagnostic complexity while maintaining precision.
2Reliability
If epigenetic patterns are used for risk stratification, then clinical outcome prediction improves, but the number of required tests and analysis increases
Solution Approach 1:
The patent creates a universal epitype classification system that serves multiple functions simultaneously: disease classification, risk stratification, treatment selection, and outcome prediction. This multi-functional system eliminates the need for separate testing protocols for each clinical question, reducing the overall number of tests required while improving comprehensive patient management.
Solution Approach 2:
The patent performs preliminary categorization of patients into epitypes based on DNA methylation patterns before treatment decisions are made. This preliminary classification consolidates multiple pieces of information (epigenetic status, genetic mutations, clinical features) into a single integrated category that guides subsequent treatment selection, reducing the need for multiple sequential tests.
3Adaptability or versatility
If comprehensive epigenetic profiling is implemented, then treatment personalization improves, but cost and resource requirements increase
Solution Approach 1:
The patent applies local quality analysis by focusing on specific, clinically relevant DNA methylation patterns and gene signatures rather than performing exhaustive genome-wide epigenetic profiling. Each epitype is defined by characteristic methylation patterns at specific genomic loci, allowing personalized treatment decisions based on targeted analysis of the most informative epigenetic features.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the accuracy of disease classification and treatment by accounting for epigenetic variations, improving clinical outcomes and survival rates in AML patients.
Implementation Method 1
DNA methylation is a stable, yet reversible epigenetic modification involving the covalent addition of a methyl group to the 5′ carbon of cytosines in cytosine-guanine dinucleotides (CpG)
Data Source
AI summary
The present disclosure provides kits and/or methods of detecting and identifying epigenetic patterns associated with acute myeloid leukemia and other cancers. The present disclosure also relates to treating, preventing, ameliorating, or reducing acute myeloid leukemia and other cancers.